High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial (Q42849724)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 October 2010

Language	Label	Description	Also known as
English	High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial	scientific article published on 20 October 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

phase III clinical trial

0 references

adaptive radiation therapy

0 references

1 reference

based on heuristic

inferred from title

Thomas Hundsberger

object named as

Thomas Hundsberger

10

0 references

21

object named as

Michael Weller

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

author name string

Eckhard Thiel

1

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Agnieszka Korfel

2

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Peter Martus

3

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Lothar Kanz

4

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Frank Griesinger

5

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Michael Rauch

6

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Alexander Röth

7

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Bernd Hertenstein

8

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Theda von Toll

9

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Hans-Günther Mergenthaler

11

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Malte Leithäuser

12

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Tobias Birnbaum

13

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Lars Fischer

14

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Kristoph Jahnke

15

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Ulrich Herrlinger

16

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Ludwig Plasswilm

17

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Thomas Nägele

18

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Torsten Pietsch

19

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Michael Bamberg

20

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

publication date

20 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

1036-1047

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Primary central nervous system lymphoma: biological aspects and controversies in management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment options for central nervous system lymphomas in immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic challenges in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreasing incidence rates of primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined modality therapy for primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment for primary CNS lymphoma: the next step

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970229-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(10)70229-1

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42849724&oldid=1972525571"